In December 2019, the Wuhan Municipal Health Committee (Wuhan, China) identified an outbreak of viral pneumonia cases of unknown cause. Coronavirus RNA was quickly identified in some of these patients. This novel coronavirus has been abbreviated as SARS-COV-2 and has 89% nucleotide identity with bat SARS-like-CoVZXC21 and 82% with that of human SARS-CoV1 There has since been global spread of the virus
This novel coronavirus has been designated SARS-CoV-2, and the disease caused by this virus has been designated COVID-19.
Global efforts to evaluate novel antivirals and therapeutic strategies to treat COVID-19 have intensified. There is an urgent public health need for rapid development of novel interventions.
- To evaluate the clinical effectiveness of the study drugs, relative to the control arm, in patients hospitalized with COVID-19 in improving mortality.
- Evaluate effectiveness of the study drugs, relative to the control arm, on reducing duration of hospitalization or need for mechanical ventilation, and intervention specific outcomes.